MedTrace Logo

A Study of JNJ-1761981 in Participants With Solid Tumors

NCT07525141 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Conditions

  • Neoplasms

Interventions

DRUG

JNJ-1761981

JNJ-1761981 will be administered intratumorally.

DRUG

Cetrelimab

Cetrelimab will be administered intravenously.

Sponsors & Collaborators

  • Johnson & Johnson Enterprise Innovation Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation, Inc Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2028-01-12
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07525141 on ClinicalTrials.gov